6533b7cffe1ef96bd1257d3c

RESEARCH PRODUCT

Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease

Harald IttrichRoman KloecknerT FründtMichael P. MannsThomas RodtNora SchweitzerHenning WegeFrank WackerMarcus-alexander WörnsJan B. HinrichsArndt WeinmannArndt VogelJens U. MarquardtTorsten VoigtländerMartha M. Kirstein

subject

OncologySorafenibmedicine.medical_specialtyCirrhosisTumor burdenDiseaseGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalIn patientneoplasmsbusiness.industryGastroenterologyOriginal Articlesmedicine.diseasedigestive system diseasesOncology030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matching030211 gastroenterology & hepatologybusinessmedicine.drug

description

BackgroundSorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC), but transarterial chemoembolization (TACE) is performed in individual cases with limited extrahepatic spread. The aim of this study was to compare the outcome of patients with HCC and extrahepatic disease (EHD) treated with sorafenib and TACE.MethodsA total of 172 patients with HCC and EHD treated with sorafenib (n = 98) or TACE (n = 74) at three German referral centers (Hannover, Mainz and Hamburg) were included in this study. In order to reduce selection bias, patients were matched for significant demographic differences using a propensity score analysis.ResultsPatients with liver cirrhosis, higher extrahepatic tumor burden and/or infiltration of adjacent organs/structures were significantly more often treated with sorafenib. Median overall survival (OS) was similar for sorafenib- and TACE-treated patients (7 versus 8 months, p = 0.312). In a propensity score analysis matched for demographic differences, median...

yearjournalcountryeditionlanguage
2017-04-07United European Gastroenterology Journal
https://doi.org/10.1177/2050640617716597